Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.
Vincent F Simmon;
(2009)
Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.
Trials, 10 (1).
110-.
ISSN 1745-6215
DOI: 10.1186/1745-6215-10-110
A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.
-
['material/summary:fileicon_text/html' not defined] - 111
-
subject - Published Version
-
- Available under Creative Commons: 3.0
Downloads